startups

Antibodies are specific molecules that can lock onto a particular cellular structure to start, stop or otherwise temper a biological process. Because they are so specific, antibodies are at the forefront of drug discovery. So drug companies want a faster route to step one: identifying which of the millions of possible antibodies will work against molecules that cause disease.

When partnering with larger companies, startups with a small number of carefully chosen alliances will reap the most benefits, according to new research from the University at Buffalo School of Management.

The University of Chicago’s research accelerator, Arete, is running its own experiment—how to bolster promising and novel research ideas before their merit has been recognized. Arete has created the Big Ideas Generator to help get those early stage ideas into motion.











